Sign In
Buy ATRC
$37.76
-2.39 (-5.95%)
At Close: Jul 31, 2026
Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know
11:01am, Tuesday, 10'th Feb 2026
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results
08:00am, Tuesday, 27'th Jan 2026
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
4 High-Efficiency Stocks Poised to Deliver Superior Returns
10:36am, Thursday, 22'nd Jan 2026
AtriCure tops a screen of high-efficiency stocks, joined by REV Group, Oceaneering International and Analog Devices after beating industry averages.
HARBOR CAPITAL ADVISORS, INC. Buys 4,925 Shares of AtriCure Inc (ATRC)
01:52pm, Tuesday, 20'th Jan 2026
Summary HARBOR CAPITAL ADVISORS, INC. raised its stake in AtriCure Inc (ATRC) by 17.2%, purchasing 4,925 shares to own 33,564 shares valued at about $1
AtriCure, Inc. (NASDAQ:ATRC) Receives Average Rating of “Moderate Buy” from Brokerages
02:10am, Monday, 19'th Jan 2026
Shares of AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) have received an average recommendation of "Moderate Buy" from the twelve analysts that are currently covering the firm, MarketBeat reports. O
AtriCure, Inc. (ATRC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
04:16pm, Wednesday, 14'th Jan 2026
AtriCure, Inc. (ATRC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026
10:21am, Monday, 12'th Jan 2026
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op
AtriCure, Inc. (ATRC) Soars to 52-Week High, Time to Cash Out?
10:15am, Friday, 09'th Jan 2026
AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AtriCure, Inc. (NASDAQ:ATRC) Receives Average Recommendation of “Moderate Buy” from Brokerages
01:47am, Thursday, 25'th Dec 2025
AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven ratings firms that are covering the stock, Marketbeat.com reports. One re
AtriCure, Inc. (NASDAQ:ATRC) Given Consensus Recommendation of “Moderate Buy” by Analysts
01:46am, Thursday, 25'th Dec 2025
Shares of AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) have been given an average rating of "Moderate Buy" by the eleven brokerages that are covering the firm, Marketbeat.com reports. One research
Has AtriCure (ATRC) Outpaced Other Medical Stocks This Year?
10:41am, Wednesday, 24'th Dec 2025
Here is how AtriCure (ATRC) and Ensign Group (ENSG) have performed compared to their sector so far this year.
AtriCure (ATRC) Is Up 6.32% in One Week: What You Should Know
01:01pm, Friday, 19'th Dec 2025
Does AtriCure (ATRC) have what it takes to be a top stock pick for momentum investors? Let's find out.
AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference
08:00am, Wednesday, 17'th Dec 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
ATRC Treats First Patients Using Novel Dual-Energy PFA-RFA Platform
11:30am, Friday, 12'th Dec 2025
AtriCure's first patients treated with its dual-energy PFA-RFA platform mark a key step as it moves toward a clinical trial next year.
AtriCure Announces the First Patients Treated with Novel Dual Energy Platform
08:00am, Thursday, 11'th Dec 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op
